Summary
Othman Guenoun
Business Developer
Technology
- In the event of an acute accident, concentrations of the biomarker studied rise significantly before gradually decreasing over the following seven days.
- However, if these levels remain high, this can lead to harmful inflammation.
- Researchers have identified molecules that can improve the prognosis of at-risk patients, stratified using the kit.
- A rapid point-of-care diagnostic kit accompanies this therapeutic strategy to reduce or counteract the levels of the molecule: a personalized treatment approach
Market
- Stratification of elderly patients after fractures.
- Treatment of post-traumatic inflammation in elderly patients (fractures: femoral neck, hip, etc.)
- Treatment of inflammation
- Treatment of sepsis
Development status
- In vitro and in vivo proof of concept of the molecule’s efficacy: in vitro on muscle and immune cells, in vivo on aged mice recapitulating the patient’s health conditions.
- In progress: Chemical optimization of the molecule, continuation of in vivo proof of concept, pharmacokinetics, pharmacodynamics, mechanistic analysis of how the molecules work.
IP
- Patent application filed in 2021 (biomarker + kit)
- Second application currently being drafted (treatment)
Valorisation strategy
- Start-up
- Licensing